Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

The world is less than a week into 2019 and already universities are proving they have every intention of building and expanding on the historic successes of the past 12 months – stay tuned for the annual data review in this month’s magazine. There is Friday’s acquisition of CoreBiome, a US-based genomic and informatics technology spinout…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.